---
title: "Gilead Sciences, Inc. (GILD.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/GILD.US.md"
symbol: "GILD.US"
name: "Gilead Sciences, Inc."
industry: "Biotechnology"
---

# Gilead Sciences, Inc. (GILD.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.gilead.com](https://www.gilead.com) |

## Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and A...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: C (0.42)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 55 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.40% |  |
| Net Profit YoY | 1672.92% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 8.29 |  |
| Dividend Ratio | 2.09% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 187.49B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 29.44B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 40.57% | A |
| Profit Margin | 28.90% | A |
| Gross Margin | 78.84% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.40% | C |
| Net Profit YoY | 1672.92% | A |
| Total Assets YoY | 0.05% | C |
| Net Assets YoY | 17.52% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 345.98% | C |
| OCF YoY | 2.40% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.50 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 61.68% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Gilead Sciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "40.57%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "28.90%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "78.84%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.40%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "1672.92%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.05%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "17.52%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "345.98%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "2.40%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "61.68%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 22.03 | 31/604 | 23.88 | 22.56 | 19.25 |
| PB | 8.29 | 355/604 | 7.43 | 7.16 | 6.97 |
| PS (TTM) | 6.37 | 115/604 | 5.27 | 4.92 | 4.71 |
| Dividend Yield | 2.09% | 6/604 | 2.87% | 2.73% | 2.55% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **30**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 17 | 57% |
| Overweight | 5 | 17% |
| Hold | 6 | 20% |
| Underweight | 1 | 3% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 151.59 |
| Highest Target | 159.00 |
| Lowest Target | 103.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/GILD.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/GILD.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/GILD.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.